Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BRL-26921

Known as: BRL 26921, BRL26921 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1987
1987
We report the results of two consecutive studies using intravenous bolus injections of streptokinase (SK) or acylated plasminogen… Expand
Is this relevant?
Review
1987
Review
1987
Thrombolytic therapy was used for 57 patients with acute and sub-acute lower limb arterial ischaemia. In the first 34 patients a… Expand
Is this relevant?
1985
1985
The role of thrombus-binding in the fibrinolytic response to the acylated streptokinase.plasminogen activator complex, BRL 26921… Expand
Is this relevant?
1985
1985
The main goal of therapeutic thrombolysis in acute myocardial infarction is early reperfusion of acutely obstructed coronary… Expand
Is this relevant?
1985
1985
BRL 26921 is a protected plasminogen-streptokinase complex with selective affinity for thrombus. When given intravenously within… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1985
1985
The effects of BRL 26921, an active-site acylated streptokinase-plasminogen complex, on the fibrinolytic and coagulation systems… Expand
Is this relevant?
1984
1984
BRL 26921 is the p- anisoyl derivative of the primary streptokinase-human plasminogen complex in which the acyl group is… Expand
Is this relevant?
1984
1984
In view of current interest in the possibility of rapid, high-dose administration of thrombolytic agents by the intravenous route… Expand
Is this relevant?
1981
1981
Abstract The fibrinolytic and thrombolytic properties of BRL 26921, a p-anisoylated streptokinase-plasminogen complex, were… Expand
Is this relevant?